Also trades as: NYMX (NASDAQ) · $vol 0M
NYMXF OTC
Nymox Pharmaceutical Corporation
1W: -68.0%
1M: +15900.0%
3M: -73.3%
YTD: -31.3%
1Y: -44.4%
3Y: -93.9%
5Y: -98.4%
$0.03
+0.00 (+0.00%)
Weekly Expected Move ±4945.7%
$-3
$-2
$0
$2
$3
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$0
+0.0% ▲
Gross Profit
-$1K
+90.9% ▲
Operating Income
-$4M
+48.7% ▲
Net Income
-$4M
+49.2% ▲
EPS (Diluted)
$-0.05
+50.3% ▲
EBITDA
-$4M
+51.4% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Revenue | $5K | $0 | $0 | $0 | $0 |
| YoY Growth | -95.7% | -100.0% | +0.0% | +0.0% | +0.0% |
| Cost of Revenue | $13K | $12K | $12K | $11K | $1K |
| Gross Profit | -$8K | -$12K | -$12K | -$11K | -$1K |
| Gross Margin | -160.0% | — | — | — | — |
| R&D Expenses | $8M | $7M | $4M | $4M | $3M |
| SG&A Expenses | $4M | $6M | $3M | $4M | $1M |
| Operating Expenses | $12M | $12M | $7M | $8M | $4M |
| Operating Income | -$12M | -$13M | -$7M | -$8M | -$4M |
| Operating Margin | -234400.0% | — | — | — | — |
| Interest Expense | $42K | $39K | $43K | $61K | $226K |
| Income Before Tax | -$12M | -$13M | -$7M | -$9M | -$4M |
| Tax Expense | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$12M | -$13M | -$7M | -$9M | -$4M |
| Net Margin | -234760.0% | — | — | — | — |
| EPS (Diluted) | $-0.16 | $-0.15 | $-0.07 | $-0.10 | $-0.05 |
| EBITDA | -$12M | -$12M | -$7M | -$9M | -$4M |
| Shares Outstanding | 74M | 82M | 89M | 92M | 94M |